Selenok: A Potential Drug Target and Biomarker for Cancer Treatment

Target Name: SELENOK

NCBI ID: G58515

SELENOK

Selenok: A Potential Drug Target and Biomarker for Cancer Treatment

SELENOK (HSPC030) is a drug target and a biomarker that is being studied for its potential role in treating various diseases, including cancer. Selenok is a small protein that is expressed in many different tissues throughout the body, including the brain, heart, and kidneys. It is involved in a number of different processes in the body, including blood cell formation and immune function.

One of the main things that makes Selenok an interesting drug target is its role in the development and progression of cancer. Cancer is a disease that can arise from a variety of different factors, including mutations in DNA, abnormal cell division, and inflammation. Many studies have shown that Selenok is involved in these processes, which makes it a potential target for cancer treatments.

One of the ways that selenok is thought to contribute to cancer development is by regulating the activity of cells that are involved in the formation of blood vessels. Blood vessels are essential for the delivery of oxygen and nutrients to cancer cells, which is why targeting the formation of blood vessels is a potential strategy for treating cancer. Selenok has been shown to play a role in regulating the production of new blood vessels, which could make it an attractive target for cancer treatments.

Another way that selenok may contribute to cancer development is by regulating the activity of immune cells. The immune system is an essential part of the body's defense against cancer, and it is important for targeting and destroying cancer cells. Selenok has been shown to interact with immune cells and may help to regulate their activity. This could make it an attractive target for cancer treatments that target the immune system.

In addition to its potential role in cancer development, selenok is also being studied for its potential as a biomarker. A biomarker is a substance that is produced by the body that can be used as a sign of the presence of a particular disease or condition. Studying the levels of selenok in different tissues and fluids, such as blood, saliva, and urine, could help to diagnose and monitor a variety of different diseases. For example, selenok levels have been shown to be elevated in a variety of diseases, including cancer, which could make it an attractive biomarker for these conditions.

Overall, Selenok is an interesting drug target and biomarker that is being studied for its potential role in treating a variety of different diseases. Its role in cancer development and its potential as a biomarker make it an attractive target for further research. As the field of pharmacology continues to evolve, it is likely that the role of Selenok and other protein candidates in the treatment of cancer and other diseases will continue to grow.

Protein Name: Selenoprotein K

Functions: Required for Ca(2+) flux in immune cells and plays a role in T-cell proliferation and in T-cell and neutrophil migration (By similarity). Involved in endoplasmic reticulum-associated degradation (ERAD) of soluble glycosylated proteins (PubMed:22016385). Required for palmitoylation and cell surface expression of CD36 and involved in macrophage uptake of low-density lipoprotein and in foam cell formation (By similarity). Together with ZDHHC6, required for palmitoylation of ITPR1 in immune cells, leading to regulate ITPR1 stability and function (PubMed:25368151). Plays a role in protection of cells from ER stress-induced apoptosis (PubMed:20692228). Protects cells from oxidative stress when overexpressed in cardiomyocytes (PubMed:16962588)

The "SELENOK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SELENOK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets